SGO 2026 – GSK bucks the B7-H4 trend
The group impresses in ovarian and endometrial cancers.
SystImmune starts another first-line phase 3
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
Gilead buys what it tried with Tubulis
A $3.15bn deal follows a December 2024 option agreement.
Henlius starts a pivotal journey to catch Pfizer
The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
BioNTech's patritumab me-too advances
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
